Therefore, we proposed that the combination of AZD8055 and EGFR inhibitors would suppress the growth of pancreatic cancer cells with greater efficacy than single treatment because, in addition to AKT kinase, the EGFR pathway also involves many other substrates such as ERK, which is dysregulated in tumor cells and promotes tumor progression [42]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.